Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

The jab, known as mRNA-4359 and developed by Moderna, is aimed at people with advanced melanoma, lung cancer and other solid ...

Researchers described results as 'an important first step' in potentially developing new treatment for people with advanced ...

But what is the vaccine and how does it work? The vaccine, known as BNT116, utilises messenger RNA (mRNA), the same technology used in the Covid-19 vaccines. Patient Janusz Racz receives an ...

The novel vaccine, BNT116, made by the German biotech company BioNTech, uses messenger RNA (mRNA) to present markers from the tumor to the patient’s immune system so it can recognize and fight ...

German biotech firm BioNTech developed this mRNA-based inoculation called BNT116. The vaccine works by activating the immune system so that it recognizes and combats cancer cells. The official ...

Researchers leading the trial have said that BioNTech’s BNT116 vaccine could improve survival rates among people with the disease, and hope that it could eventually become the standard of care ...

Known as BNT116, and made by German biotechnology company BioNTech, the vaccine targets non-small cell lung cancer, or NSCLC, the most common type of lung cancer. Unlike vaccines to prevent ...

Additionally, the advancement of BioNTech’s lung cancer vaccine, BNT116, into Phase 1 trials adds another layer of potential to the company’s robust pipeline. BNT116 employs mRNA technology ...